Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Ardelyx (Nasdaq: ARDX) will report third quarter 2025 financial results and provide a business update on Thursday, October 30, 2025 at 4:30 p.m. ET. The company will host a live conference call and simultaneous webcast accessible from the Investors section of its website at www.ardelyx.com. Domestic dial-in is (877) 346-6112 and international dial-in is (848) 280-6350. The live webcast will be archived and available for replay for 30 days after the call.
Ardelyx (Nasdaq: ARDX) riporterà i risultati finanziari del terzo trimestre 2025 e fornirà un aggiornamento sull'attività aziendale il giovedì 30 ottobre 2025 alle 16:30 ET. L'azienda terrà una conferenza telefonica in diretta e una webcast simultanea accessibili dalla sezione Investitori del proprio sito web all'indirizzo www.ardelyx.com. Il numero di linea nazionale è (877) 346-6112 e quello internazionale è (848) 280-6350. La webcast in diretta sarà archiviata e disponibile per la riproduzione per 30 giorni dopo la chiamata.
Ardelyx (Nasdaq: ARDX) reportará los resultados financieros del tercer trimestre de 2025 y proporcionará una actualización comercial el jueves 30 de octubre de 2025 a las 4:30 p.m. ET. La empresa organizará una llamada de conferencias en vivo y una transmisión web simultánea accesibles desde la sección de Inversionistas de su sitio web en www.ardelyx.com. El número de discado nacional es (877) 346-6112 y el de discado internacional es (848) 280-6350. La transmisión web en vivo quedará grabada y estará disponible para su reproducción durante 30 días después de la llamada.
Ardelyx (나스닥: ARDX)가 2025년 3분기 재무 실적을 발표하고 2025년 10월 30일 목요일 오후 4:30(Eastern Time)에 비즈니스 업데이트를 제공할 예정입니다. 회사는 라이브 컨퍼런스 콜과 동시 생중계를 웹사이트의 투자자 섹션에서 확인할 수 있도록 진행합니다. www.ardelyx.com에서 확인하십시오. 국내 다이얼인은 (877) 346-6112이고 국제 다이얼인은 (848) 280-6350입니다. 라이브 생중계는 통화 후 30일 동안 재생 가능합니다.
Ardelyx (Nasdaq: ARDX) publiera les résultats financiers du troisième trimestre 2025 et fournira une mise à jour sur les activités le jeudi 30 octobre 2025 à 16h30 ET. L'entreprise organisera une conférence téléphonique en direct et une diffusion Web simultanée, accessibles depuis la section Investisseurs de son site Web à l'adresse www.ardelyx.com. Le numéro national est (877) 346-6112 et le numéro international est (848) 280-6350. La diffusion Web en direct sera archiévée et disponible en réécoute pendant 30 jours après l'appel.
Ardelyx (Nasdaq: ARDX) wird die Finanzergebnisse des dritten Quartals 2025 berichten und ein Geschäftsupdate am Donnerstag, 30. Oktober 2025 um 16:30 Uhr ET geben. Das Unternehmen wird einen Live-Konferenzanruf und eine gleichzeitige Webcast anbieten, erreichbar im Bereich Investoren auf der Website unter www.ardelyx.com. Die nationale wählnummer ist (877) 346-6112 und die internationale Wählnummer ist (848) 280-6350. Der Live-Webcast wird aufgezeichnet und steht 30 Tage nach dem Anruf zur Wiedergabe zur Verfügung.
Ardelyx (بينانس: ARDX) ستعلن عن نتائجها المالية للربع الثالث من 2025 وتقدم تحديثًا للأعمال في يوم الخميس، 30 أكتوبر 2025 في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة. ستوفر الشركة مكالمة مؤتمر حيéة وبثاً مباشراً عبر الويب متزامناً يمكن الوصول إليه من قسم المستثمرين في موقعها على الويب على العنوان www.ardelyx.com. رقم الاتصال المحلي هو (877) 346-6112 ورقم الاتصال الدولي هو (848) 280-6350. سيتم حفظ البث المباشر عبر الويب وسيكون متاحاً لإعادة التشغيل لمدة 30 يوماً بعد المكالمة.
Ardelyx（纳斯达克：ARDX） 将公布2025 年第三季度的财务业绩并于2025 年 10 月 30 日，星期四，美国东部时间下午 4:30提供业务更新。公司将举行现场电话会议并提供同步网络广播，可在其网站的投资者部分通过 www.ardelyx.com 访问。国内拨号为（877）346-6112，国际拨号为（848）280-6350。现场网络广播将被存档，通话后可重复收听，直到 30 天后无法再收听。
- None.
- None.
Conference call scheduled for 4:30 p.m. Eastern Time
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, October 30, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2025.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Ardelyx (ARDX) report third quarter 2025 results?
How can investors join the Ardelyx (ARDX) October 30, 2025 conference call?
Where can I listen to the Ardelyx (ARDX) Q3 2025 webcast?
Will the Ardelyx (ARDX) Q3 2025 webcast be available after the call and for how long?
What time is the Ardelyx (ARDX) earnings call for investors in Eastern Time?
